Epstein-Barr virus-associated lymphoproliferative diseases

Viracta Receives Fast Track Designation for Nanatinostat Combination for the Treatment of EBV-Associated Lymphomas

Retrieved on: 
Tuesday, November 12, 2019
Medical specialties, Organ systems, Medicine, RTT, Infectious causes of cancer, Anatomical pathology, Nasopharynx cancer, Pharynx, Lymphoma, Sjögren syndrome, Epstein-Barr virus-associated lymphoproliferative diseases, Epstein–Barr virus infection

The Company previously announced interim data from the Phase 1b portion of an ongoing Phase 1b/2a clinical trial of nanatinostat in combination with the antiviral valganciclovir in patients with relapsed/refractory EBV-associated lymphomas.

Key Points: 
  • The Company previously announced interim data from the Phase 1b portion of an ongoing Phase 1b/2a clinical trial of nanatinostat in combination with the antiviral valganciclovir in patients with relapsed/refractory EBV-associated lymphomas.
  • "We believe our approach to EBV-associated lymphomas represents a novel treatment option for patients where the presence of EBV has not historically been actionable.
  • The nanatinostat and valganciclovir combination is being investigated in EBV-associated lymphomas in an ongoing Phase 2 clinical trial [ NCT03397706 ].
  • Viracta is pursuing application of this Kick and Kill treatment approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other viral-related cancers.

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Herpesviridae, Viruses, Medical specialties, Infectious causes of cancer, Viral proteins, Lymphoma, Epstein–Barr virus, Epstein–Barr virus infection, Epstein-Barr virus-associated lymphoproliferative diseases

The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.

Key Points: 
  • The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.
  • Approximately 95% of the world's adult population is infected with Epstein-Barr Virus (EBV), yet infections are commonly asymptomatic.
  • Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patients' life.
  • The Company's proprietary lead molecule, nanatinostat, is currently being evaluated in combination with valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas.

Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

Retrieved on: 
Friday, September 13, 2019
Infectious causes of cancer, Medical specialties, Lymphoma, Epstein–Barr virus, Medicine, Clinical medicine, Multiple sclerosis, Viral proteins, Transplantation medicine, Epstein-Barr virus-associated lymphoproliferative diseases, Epstein–Barr virus infection

The data are featured in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, September 11-13, 2019.

Key Points: 
  • The data are featured in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, September 11-13, 2019.
  • ATA188 is an off-the-shelf, allogeneic T-cell immunotherapy that targets Epstein-Barr Virus (EBV)-infected B cells believed to play a role in the pathogenesis of MS.
  • The reported initial data as of July 29, 2019 are from a Phase 1, multicenter, open-label, dose-escalation study evaluating the safety and efficacy of ATA188 in patients with progressive forms of MS.
  • Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with progressive forms of multiple sclerosis

Juntendo University Research: IPS Based Approach for Treating Virus-induced Tumors

Retrieved on: 
Monday, September 9, 2019
Cancer, Infectious causes of cancer, Branches of biology, Epstein–Barr virus, Viral proteins, Virology, Epstein-Barr virus-associated lymphoproliferative diseases, Natural killer cell

Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.

Key Points: 
  • Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.
  • Since ENKL tumors are commonly infected with the Epstein-Barr virus (EBV), T-cells recognize these tumor cells by the presence of viral proteins.
  • T-cells from patients' blood, which were accustomed to identifying ENKL tumors, were first collected and then genetically modified into stem cells.
  • Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.

Juntendo University Research: IPS Based Approach for Treating Virus-induced Tumors

Retrieved on: 
Monday, September 9, 2019
Cancer, Infectious causes of cancer, Branches of biology, Epstein–Barr virus, Viral proteins, Virology, Epstein-Barr virus-associated lymphoproliferative diseases, Natural killer cell

Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.

Key Points: 
  • Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.
  • Since ENKL tumors are commonly infected with the Epstein-Barr virus (EBV), T-cells recognize these tumor cells by the presence of viral proteins.
  • T-cells from patients' blood, which were accustomed to identifying ENKL tumors, were first collected and then genetically modified into stem cells.
  • Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.